Tel: 561-316-3330
Email: mdnewsmagazine@infomeddnews.com
Home Blog Page 44

Marketing for Doctors:10 Best Proven Activities for Your Practice

Marketing for Doctors

In today’s digital world, doctors cannot rely on traditional marketing methods alone to attract and retain patients. Doctors in Houston must utilize digital marketing strategies and tools to stay ahead of the competition. Digital Spotlight can help your practice reach a wider audience and build trust with potential patients.

If you want the best ai video generator you can visit deeep brain. They provide one of the best ai video editor services.

If you want the best on-line digital marketing course, find one that covers everything in detail.

Here are 10 proven activities you can use to market your practice in the modern world. These activities will help you build an effective online presence that will drive more leads and increase patient engagement.

1. Provide Quality Healthcare Services

Most individuals rely on referrals from family members and friends wherever they need doctors’ services. Therefore, you should put your best foot forward when providing services to your existing patients to get referrals. Identify your patient’s needs and provide tailor-made solutions. Listen to your patients and offer quality customer experience to ensure they return and bring referrals.

2. Build a Professional and User-Friendly Website

A recent survey indicated that 86% of customers prefer learning about a company’s products or services from its website. Building a professional website is your best chance to improve customer experience and showcase your services to potential clients.

Build a secure, user-friendly, easy-to-navigate website with all relevant buttons like appointment scheduling, talking to a doctor, and online billing. Hiring a professional to build you one may seem like an expensive venture, but it’s worth every penny.

3. Invest in SEO

Doctors can leverage Search Engine Optimization to drive traffic to their websites. Search engines like Google are valuable resources when wanting to expand your patient base. However,60% of Google’s traffic goes to the top three websites. Hence, it’s imperative to employ the best SEO strategies to ensure your practice appears in the first three search results.

Use relevant keywords and establish your site authority by posting fresh and relevant content regularly. Get relevant backlinks from authority sites to increase traffic and bookings that could turn into conversions.

4. Leverage Social Media

In a study to determine the impact of social media on health,41% of the participants said that social media impacted their choice of doctor, medical facility, or hospital. Social media is a valuable platform for building your brand credibility, establishing an online presence, and engaging your patients.

Establish yourself as an authority by sharing valuable information, answering patient questions, and educating your patients on healthy living, disease prevention, and first aid tips. Encourage them to share this information widely to drive traffic to your social media pages and increase conversions.

5. Email Marketing

Email is one of the most effective communication methods between doctors and patients. Remind patients of upcoming appointments and events at your facility. Ask them to subscribe to your newsletter and carry out regular promotions to motivate your regular patients.

6. List Your Practise On Google My Business

Google My Business is a free listing tool by Google to boost the appearance of your practice on search engines and boost local SEO. You must create a business profile to connect with your patients, update new services, and collect invaluable feedback. A patient looking for a doctor in your area will most likely search for doctors near them, and listing your practice increases the chances of appearing on top of search results and boosting conversions.

7. Start a Blog

Starting a medical blog is a great way of marketing your services as a doctor. It increases your online presence and demonstrates your expertise in your specialization. A blog is a great way of increasing patient engagement, building trust, inspiring referrals, and attracting new patients.

Use the blog to address your patients’ greatest concerns, advertise your services and explain how they can benefit from them. Use your blog to educate your patients on new technologies and emerging trends in healthcare to build their trust and increase your brand credibility.

8. Embrace Video Marketing

Video Marketing is a surefire way of driving organic traffic to your website and engaging your patients. Create short videos explaining a certain medical procedure or how a certain drug works, and ask your viewers to leave questions in the comment section. You can also record a patient testimonial or a welcome message on the website. Create short videos and add links to your landing page. Patients can share these videos on their social media pages if they find them helpful and reach a wider audience.

9. Request Your Patients to Leave Online Reviews

Online reviews can significantly impact your reputation as a doctor and attract new clients to your practice. Most patients will look at online reviews when looking for a new doctor. Request your patients to leave honest feedback and use it to improve your practice. Respond to negative and positive reviews without bias to build trust and attract new customers.

10. Budget For Paid Search Advertising

Paid search is a clever digital marketing strategy to gain organic SEO and rank higher in search engines. It’s a cost-effective way of ensuring your name appears every time a potential client searches for a doctor in your area. Track your marketing campaigns for details of how many clients clicked on your ad, their locations, and ROI, and use the statistics to improve your marketing strategies.

Final Thoughts

Doctors should implement effective marketing strategies to increase patient engagement and build trust. By employing the ten practices discussed above, your healthcare business can stay ahead of your competition and achieve greater conversions.

 

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company’s MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, and have been published in The Lancet.

The article titled “Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a randomised phase 3 trial” is now available online and will be published in a future print issue of The Lancet.

“The results from the MOTION pivotal Phase 3 study provide compelling evidence that vimseltinib can address the unmet medical need in TGCT for an effective and well-tolerated therapy without cholestatic hepatotoxicity,” said Hans Gelderblom, M.D., Ph.D., Chair of the Department of Medical Oncology at Leiden University Medical Center and senior author of the manuscript. “In addition to its robust antitumor activity and tolerability, vimseltinib also demonstrated clinically significant functional and symptomatic improvements in key quality-of-life measures, which can provide long-term, meaningful benefits to TGCT patients.”

“Building upon the strong efficacy results disclosed previously at topline, we are excited to share details on the statistically significant and clinically meaningful improvements that vimseltinib offered TGCT patients across all six key secondary endpoints, along with its favorable safety profile,” said Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera. “We remain on track to submit an NDA for vimseltinib in the second quarter of 2024, and an MAA in the third quarter of 2024, and look forward to bringing this important new therapy to TGCT patients globally.”

In addition to the results from the MOTION pivotal Phase 3 study, the Company will also be presenting a trial-in-progress poster for the ongoing Phase 1/2 study of DCC-3116 in combination with ripretinib at the 2024 ASCO Annual Meeting.

Both presentations are available on the Company’s website at www.deciphera.com/presentations-publications. Presentation details are as follows:

 

Abstract Number: 11500
Title: Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.
Presenter: William D. Tap, M.D., FASCO, Memorial Sloan Kettering Cancer Center
Presentation Date: Monday, June 3, 2024
Presentation Time: 3:00 – 3:12 PM CT
Key Highlights:

 

  • Study Design: The MOTION pivotal Phase 3 study is a two-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vimseltinib in patients with TGCT not amenable to surgery with no prior anti-CSF1/CSF1R therapy (prior therapy with imatinib or nilotinib allowed).
    • In Part 1, patients (n=123) were randomized two-to-one to receive either 30 mg twice weekly of vimseltinib (n=83) or placebo (n=40) for 24 weeks. The results for Part 1 of the study are based on a data cutoff date of August 22, 2023.
    • The open-label Part 2 portion of MOTION, in which patients from both the vimseltinib and placebo arms receive treatment with vimseltinib, remains ongoing.
  • ORR: The primary endpoint of the study is ORR at Week 25 as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent radiologic review (IRR).
    • The study met its primary endpoint in the intent-to-treat (ITT) population demonstrating statistically significant and clinically meaningful improvement versus placebo in ORR at Week 25 based on IRR per RECIST v1.1.
    • In the ITT population, the ORR at Week 25 was 40% (95% CI: 29%, 51%) for the vimseltinib arm and 0% (95% CI: 0%, 9%) for the placebo arm resulting in a response difference (vimseltinib versus placebo) of 40% (95% CI: 29%, 51%) (p<0.0001).
  • Secondary Endpoints: In addition to meeting the primary endpoint, the study also achieved statistically significant and clinically meaningful improvements versus placebo in all six key secondary endpoints assessed at Week 25 including ORR by tumor volume score (TVS), active range of motion (ROM), physical function, stiffness, quality of life, and pain.
    • ORR by TVS: The ORR at Week 25 based on IRR per TVS was 67% (95% CI: 56%, 77%) for the vimseltinib arm and 0% (95% CI: 0%, 9%) for the placebo arm (p<0.0001).
    • Active ROM: Treatment with vimseltinib demonstrated an improvement in mean change from baseline in active ROM at Week 25 of 18.4% versus a 3.8% improvement for placebo (p=0.0077).
    • Physical Function by PROMIS-PF: Treatment with vimseltinib demonstrated an improvement in mean change from baseline in PROMIS-PF at Week 25 of 4.6 versus 1.3 for placebo (p=0.0007).
    • Worst Stiffness Numeric Rating Scale (NRS): Patients treated with vimseltinib reported a decrease of 2.1 versus 0.3 for placebo in worst stiffness (p<0.0001).
    • Quality of Life by EuroQol Visual Analogue Scale (EQ-VAS): The mean change from baseline for EQ-VAS was significantly higher with 13.5 in the vimseltinib arm versus 6.1 in the placebo arm (p=0.016).
    • Brief Pain Inventory (BPI) Worst Pain Response Rate: The BPI worst pain response rate was 48% for patients receiving vimseltinib versus 23% for placebo (p=0.0056).
  • Safety and Tolerability:
    • Vimseltinib was well tolerated with most treatment-emergent adverse events (TEAEs) were grade 1 or 2.
    • There was no evidence of cholestatic hepatotoxicity, drug-induced liver injury, or hair hypopigmentation.
    • Serum enzyme elevations were consistent with the known mechanism of action of CSF1R inhibitors.
    • TEAEs leading to treatment discontinuation was 6% in the vimseltinib arm.
  • If approved, vimseltinib offers an effective systemic treatment to patients with TGCT and provides proven functional health and symptomatic benefit to a population living with substantial morbidity and limited treatment options.

Abstract Number: TPS11587
Title: DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.
Presenter: Sreenivasa Chandana, M.D., Ph.D., START Midwest, The Cancer & Hematology Centers
Session Date: Saturday, June 1, 2024
Session Time: 1:30 – 4:30 PM CT
Key Highlights:

  • This is a phase 1/2, multicenter study designed to evaluate the safety, tolerability, and efficacy of DCC-3116 in combination with ripretinib.
    • In Part 1, eligible patients will receive escalating oral doses of DCC-3116 combined with ripretinib 150 mg once daily (QD); the safety will be evaluated and the recommended phase 2 dose (RP2D) will be determined.
    • In Part 2, eligible patients will receive the RP2D of DCC-3116 in combination with ripretinib 150 mg QD; antitumor activity will be evaluated.
  • The trial is currently enrolling in the phase 1 dose escalation portion.

7 Wellness Tips for Chiropractic Patients to Speed Healing and Maintain Health

Chiropractic Patients, wellness tips

Chiropractic care is a vital component of a holistic approach to health and wellness. Beyond alleviating pain and correcting spinal misalignments, chiropractic adjustments can enhance overall bodily function. To maximize the benefits of chiropractic care and ensure a speedy recovery, patients should incorporate several wellness practices into their daily routines. Here are seven essential wellness tips for chiropractic patients aiming to speed healing and maintain optimal health.

Exercise Regularly

Regular exercise is crucial for maintaining the benefits of chiropractic care. Physical activity helps strengthen muscles, improve flexibility, and enhance circulation, all of which contribute to better spinal health.

  • Types of Exercises: Engage in a balanced exercise regimen that includes cardiovascular activities, strength training, and flexibility exercises. Activities such as walking, swimming, and yoga can be particularly beneficial.
  • Consistency: Aim for at least 150 minutes of moderate-intensity exercise per week. Consistency is key to reaping the benefits of regular physical activity.
  • Tailored Programs: Consult with your chiropractor to develop an exercise program tailored to your specific needs and capabilities. This personalized approach can prevent injuries and ensure that the exercises complement your chiropractic treatments.

Practice stress management.

Stress has a significant impact on physical health, including spinal health. Chronic stress can lead to muscle tension, poor posture, and exacerbated pain.

  • Relaxation Techniques: Incorporate relaxation techniques such as deep breathing exercises, meditation, and progressive muscle relaxation into your daily routine.
  • Mindfulness and Yoga: Practices like mindfulness meditation and yoga not only reduce stress but also improve flexibility and strength, supporting your chiropractic care.
  • Healthy Lifestyle Choices: Ensure you get enough sleep, maintain a balanced diet, and engage in activities you enjoy to keep stress levels in check.

Emphasize Nutrition

Nutrition plays a pivotal role in the healing process and overall health. A well-balanced diet provides the essential nutrients needed for tissue repair and overall well-being.

  • Anti-Inflammatory Foods: Incorporate anti-inflammatory foods such as fruits, vegetables, nuts, seeds, and fatty fish into your diet. These foods can help reduce inflammation and promote healing.
  • Hydration: Stay hydrated by drinking plenty of water throughout the day. Proper hydration supports joint health and aids in the elimination of toxins from the body.
  • Supplements: Discuss with your chiropractor whether you need any supplements, such as omega-3 fatty acids, vitamin D, or calcium, to support your specific health needs.

Take breaks from prolonged sitting.

Prolonged sitting can lead to poor posture and spinal misalignments, counteracting the benefits of chiropractic care.

  • Frequent Breaks: Take short breaks every 30 to 60 minutes to stand up, stretch, and move around. This helps reduce the strain on your spine and improve circulation.
  • Ergonomic Workspaces: Ensure your workstation is ergonomically designed to support proper posture. Use an adjustable chair, keep your computer screen at eye level, and position your feet flat on the floor.
  • Stretching Exercises: Incorporate simple stretching exercises into your routine, focusing on the neck, shoulders, and lower back to alleviate tension.

Choose the right shoes.

Footwear significantly impacts your posture and spinal health. Wearing the right shoes can prevent or alleviate back pain and support overall alignment.

  • Supportive Footwear: Choose shoes that provide adequate arch support and cushioning. Avoid high heels and flat shoes with little support, as they can contribute to spinal misalignments.
  • Custom Orthotics: If you have specific foot issues, consider custom orthotics recommended by your chiropractor. These inserts can provide additional support and help correct gait abnormalities.
  • Regular Replacement: Replace your shoes regularly, especially if they show signs of wear and tear, to ensure continued support for your feet and spine.

Avoid long hours of standing.

While sitting for extended periods is detrimental, standing for long hours can also cause problems such as lower back pain and fatigue.

  • Balanced Approach: Alternate between sitting and standing throughout the day to balance the load on your spine.
  • Supportive Flooring: Use anti-fatigue mats if you have to stand for long periods. These mats can reduce the strain on your legs and lower back.
  • Proper Footwear: As with sitting, ensure you wear supportive shoes when standing for prolonged periods to maintain good posture and reduce discomfort.

Passive Stretches for Large Muscles

Passive stretching is a gentle way to increase flexibility and reduce muscle tension without straining the muscles.

  • Daily Routine: Incorporate passive stretching exercises into your daily routine, focusing on large muscle groups such as the hamstrings, quadriceps, and hip flexors.
  • Assistance: Use props like straps or enlist the help of a partner to achieve deeper stretches without exerting yourself.
  • Post-Chiropractic Care: Perform these stretches after chiropractic sessions to maintain improved alignment and prevent stiffness.

Incorporating these seven wellness tips into your routine can significantly enhance the effects of chiropractic care. Regular exercise, stress management, proper nutrition, and ergonomic practices are essential for maintaining spinal health and overall well-being. By following these guidelines, chiropractic patients can experience faster healing and sustained health benefits. If you’re looking for a chiropractor in Brampton, consider how these wellness tips can complement your chiropractic treatments to achieve optimal health outcomes.

Additional Tips for Optimal Health

  • Regular Chiropractic Visits: Consistency with chiropractic appointments ensures that your spine stays aligned and any issues are addressed promptly.
  • Listening to Your Body: Pay attention to your body’s signals. If you experience pain or discomfort, consult with your chiropractor for advice and possible adjustments to your care plan.
  • Holistic Health Approach: Combine chiropractic care with other holistic health practices, such as massage therapy, acupuncture, and physiotherapy, for comprehensive care.

Chiropractic care is more than just adjustments; it’s a lifestyle that promotes overall health and wellness. By integrating these tips into your daily routine, you can support your body’s natural healing processes and maintain a high level of health and well-being. Whether you are visiting a Brampton chiropractor or another chiropractic professional, these wellness practices will help you get the most out of your care and enjoy a healthier life.

 

ExpressionEdits Raises $13M in Seed Funding to Advance Protein Expression Using AI-Driven Intronization Technology

ExpressionEdits
From left to right: Dr. Kärt Tomberg, CEO & Co-Founder, Dr. Leopold Parts, CTO, Dr. Rebecca Godfrey, COO. (Photo credit: ExpressionEdits)

ExpressionEdits, a biotechnology company optimizing protein expression using AI and proprietary intronization technology, announced today a $13 million seed funding round co-led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.

Founded in 2021 by Dr. Kärt Tomberg, Professor Allan Bradley, and Dr. Liliana Antunes based on research from the University of Cambridge, the company’s proprietary intronization technology revolutionizes gene design by mimicking the natural genetic landscape. By strategically incorporating multiple short noncoding DNA sequences known as introns into artificial genes, ExpressionEdits has achieved significant enhancements in gene expression which leads to better protein production.

The funding will accelerate candidate selection for preclinical studies and develop a pipeline of protein-based therapeutics. The primary focus for the pipeline will be recombinant proteins that have historically faced production and manufacturing challenges based on current technology.

“At ExpressionEdits, we’re revolutionizing gene expression by putting introns back where they belong, resulting in significant improvements in production,” said Dr. Kärt Tomberg, CEO & Co-Founder, ExpressionEdits. “Our platform empowers precise decisions on which introns to use, where to place them, and how many, unlocking unprecedented levels of protein expression. Our mission is to be the pioneers in making protein therapeutics readily available and accessible to patients.”

The company’s AI-powered platform integrates millions of biological data points with machine learning algorithms, enabling automated optimization of gene design. This transformative technology empowers ExpressionEdits to predict and prioritize key properties of genes, unlocking the production of previously elusive therapeutic proteins.

“We believe that the ExpressionEdits platform can become the fabric for any protein expression system, from antibody manufacturing to in vivo therapeutics,” said Dr. Hugo Villanueva, Investor, Octopus Ventures. “We’re excited to support Kärt and the ExpressionEdits team to revitalise healthcare through their mission of improving protein expression to produce novel genetic medicines.”

“ExpressionEdits unravels the significance and the opportunities of introns, which were once relegated to the dark matter of the human genome,” said Michael Sidler, Founding Partner at redalpine. “Their proprietary intronization technology unlocks the capacity to express highly complex molecules previously deemed unattainable, while regulating them with precision. This opens up a groundbreaking new frontier in the recombinant protein therapy space, and we firmly believe that ExpressionEdits will spearhead the growth of this rapidly expanding field.”

ExpressionEdits’ Genetic Syntax Engine is a computational gene editing platform that uses advanced AI and deep biological insights to predict and redesign genes to unlock protein expression across therapeutic modalities. The technology aims to improve the effectiveness and precision of gene therapies, allowing for lower doses to achieve therapeutic levels, thus minimizing toxicity, and expanding the genetic toolbox to further support the targeting of specific tissues, and increasing protein expression levels.

Mark Eisner MD, M.P.H. Appointed Chief Medical Officer at Vir Biotechnology

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr. Eisner will be a part of the company’s Executive Management Team and will report directly to Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer.

Mark Eisner MD comes from Sonoma Biotherapeutics, Inc., where he most recently held the position of CMO. In this role, he led all development functions which included biometrics, regulatory, clinical science, clinical operations, drug safety, and pharmacology. Prior to his most recent tenure with Sonoma Biotherapeutics, Dr. Eisner served as CMO at FibroGen where he led all development functions, which included being the Head of China clinical development and clinical operations. Dr. Eisner has also been with Genentech nearly 11 years and served as their Senior Vice President of Global Head of Product Development Immunology, Infectious Disease and Ophthalmology and was accountable for late-stage clinical development of many products including strategy, clinical trials and budget. He brings to Vir deep immunology and infectious disease expertise with clinical development experience. Dr. Eisner has an impressive track record of leading teams during times of strategically evolving portfolios.

“We are delighted to welcome Mark, a seasoned and highly respected scientist, clinician, and leader, to Vir’s Executive Management Team. His exceptional leadership skills with late-stage clinical experience and deep knowledge of immunology and infectious disease will be critical to the next phase of Vir’s growth,” said Dr. De Backer. “In addition to his proven track record of overseeing multiple products across various indications while securing breakthrough therapy designation, Mark’s visionary and enterprise mindset will be of great benefit to Vir as we focus on bringing medicine to patients with unmet medical needs.”

Dr. Eisner completed his A.B. degree in human biology at Stanford University and his M.D. degree at the University of Pennsylvania School of Medicine. He also has an M.P.H. focusing on epidemiology from the University of California Berkeley, School of Public Health. He has an impressive list of publications and patents, honors and awards, and services for professional organizations.

“I am thrilled to be joining Vir at this critical time and am looking forward to working with the talented teams to advance our clinical development programs,” said Dr. Eisner. “I have always admired the bold mission of the company. Patients have always been my guiding compass, so I am excited to have this opportunity to help translate Vir’s groundbreaking science into advances for human health.”

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the U.S. Food and Drug Administration (FDA) has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension with nighttime dosing, for the treatment of ADHD as a monotherapy or as an adjunctive therapy to approved central nervous system (CNS) stimulant medications in pediatric patients six years and older.

ONYDA XR is the first non-stimulant ADHD medication in Tris’ portfolio, the first-and-only liquid non-stimulant ADHD medication approved in the United States and the only approved non-stimulant ADHD medication with nighttime dosing. Non-stimulant ADHD therapies are an important option for patients who do not respond adequately to stimulant medication or experience negative side effects from them, and they are increasingly used as an effective alternative to stimulant treatments. ONYDA XR is expected to be available in pharmacies in the second half of 2024.

“People with ADHD require a range of therapeutic options that are designed for their individual needs, because not every medication or type of therapy works for every patient,” said Ann Childress, M.D. “The approval of ONYDA XR, the only liquid non-stimulant ADHD medication, with nighttime dosing that shifts the release profile, is a convenient option for patients needing better ADHD control.”

Tris Pharma harnessed the flexibility of its proprietary LiquiXR® technology to develop ONYDA XR, a liquid non-stimulant medication with a smooth, extended-release profile that physicians can use to treat ADHD patients either alone or in combination with stimulant therapy. This product adds to Tris’ comprehensive and expanding portfolio of leading ADHD therapies that enhance patient care for individuals with the disorder. The company’s ADHD therapies are available in both oral suspension (liquid) and solid (tablet) forms for administration to children and adults. Tris continues to grow its ADHD offerings with a pipeline of new medications that could have a substantial impact for those with the disorder.

“Securing FDA approval for ONYDA XR is not just an important milestone, but a testament to our unwavering commitment to innovating and improving outcomes for this patient population,” said Ketan Mehta, Founder and CEO at Tris Pharma. “Our relentless pursuit to offer a range of ADHD medicines to patients of all ages does not stop here, and we look forward to continuing to expand our portfolio in other ADHD indications.”

The U.S. FDA approval of ONYDA XR is based on adequate and well-controlled studies of clonidine hydrochloride extended-release tablets.

ONYDA (Clonidine hydrochloride)

PROFESSIONAL INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

ONYDA XR is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.

IMPORTANT SAFETY INFORMATION

Contraindications:

  • ONYDA is contraindicated in patients with history of a hypersensitivity reaction to clonidine.

Warnings & Precautions

  • Hypotension/Bradycardia: Treatment with ONYDA XR can cause dose-related decreases in blood pressure and heart rate. Titrate slowly and monitor vital signs frequently in patients at risk for hypotension, heart block, bradycardia, syncope, cardiovascular disease, vascular disease, cerebrovascular disease, or chronic renal failure. In patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, advise patients to avoid becoming dehydrated or overheated.
  • Somnolence/Sedation: Somnolence and sedation were commonly reported adverse reactions in clinical studies with clonidine hydrochloride extended-release tablets. Caution patients against operating heavy equipment or driving until they know how they respond to treatment with ONYDA XR. Advise patients to avoid use with alcohol.
  • Cardiac Conduction Abnormalities: The sympatholytic action of clonidine may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. There have been post-marketing reports of patients with conduction abnormalities and/or taking other sympatholytic drugs who developed severe bradycardia requiring intravenous (IV) atropine, IV isoproterenol, and temporary cardiac pacing while taking clonidine. Titrate ONYDA XR slowly and monitor vital signs frequently in patients with cardiac conduction abnormalities or patients concomitantly treated with other sympatholytic drugs.

Adverse Reactions:

  • Most common adverse reactions (incidence at least 5% and twice the rate of placebo) as monotherapy in ADHD: somnolence, fatigue, irritability, nightmare, insomnia, constipation, dry mouth.
  • Most common adverse reactions (incidence at least 5% and twice the rate of placebo) as adjunct therapy to psychostimulant in ADHD: somnolence, fatigue, decreased appetite, dizziness.

Drug Interactions:

  • CNS Depressants: Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates, or other sedating drugs. Avoid concomitant use of CNS depressants with ONYDA XR.
  • Tricyclic Antidepressants: Concomitant use of tricyclic antidepressants with clonidine can increase blood pressure and may counteract the hypotensive effects of clonidine. Monitor blood pressure and adjust dosage of ONYDA XR as needed.
  • Drugs Known to Affect Sinus Node Function or AV Nodal Conduction: Avoid use of ONYDA XR with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers and beta-blockers) due to a potential for additive effects such as bradycardia and AV block.
  • Antihypertensive drugs: Concomitant use of antihypertensive drugs with clonidine potentiates the hypotensive effects of clonidine. Monitor blood pressure and heart rate and adjust dosage of ONYDA XR accordingly in patients treated concomitantly with antihypertensives.

Use in specific population:

  • Use in patients with renal Impairment: The impact of renal impairment on the pharmacokinetics of clonidine in pediatric patients has not been assessed. The dosage of ONYDA XR must be adjusted according to the degree of impairment, and patients should be carefully monitored.
  • Use during pregnancy: Prolonged experience with clonidine in pregnant women over several decades, based on published literature, including controlled trials, a retrospective cohort study and case reports, have not identified a drug associated risk of major birth defects, miscarriage, and adverse maternal or fetal outcomes.To monitor pregnancy outcomes in women exposed to ADHD medications, including ONYDA XR, during pregnancy, healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/adhd-medications/.
  • Use during lactation: The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ONYDA XR and any potential adverse effects on the breastfed child from ONYDA XR or from the underlying maternal condition. Monitor breastfeeding infants exposed to ONYDA XR through breast milk for symptoms of hypotension and/or bradycardia such as sedation, lethargy, tachypnea, and poor feeding.

To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at 1-732-940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see ONYDA PI for full prescribing information

VUZE Medical Announces U.S. FDA 510(K) Clearance for Second-Generation Software-Based 3D Guidance System for Spine Surgery

VUZE Medical, a privately-held company aiming to transform intra-operative guidance in spinal interventions currently aided only by X-ray, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its second-generation VUZE System. The system’s current focus is on minimally invasive thoracolumbar stabilizations; however, the underlying VUZE technology is not specific to any particular anatomy, and the company intends to seek regulatory clearances for further spinal and skeletal interventions in the future. VUZE has already received eleven related patents in the U.S., Europe, China and India, including tie-ins with robotics, augmented reality (AR) and traditional hardware-based navigation.

The VUZE System is a software solution installed on an off-the-shelf PC. It operates with unmodified surgical tools, uses no markers, references or cameras, and makes 3D imaging in the operating room (OR) entirely optional. Using proprietary image processing algorithms, it overlays in real time graphical representations of standard surgical tools seen in intra-operative 2D X-ray images onto axial and sagittal cross-sections that it generates from the patient’s standard pre-operative 3D scan. The VUZE System received its initial U.S. FDA 510(k) clearance in 2022 and completed a first-in-human clinical trial in 2023.

The second-generation VUZE System supports a far broader range of surgical C-arms from all major vendors. Additionally, it accommodates more sources of 3D image data including both standard pre-operative CT and in-OR CT/CBCT scans. Its expanded functionality includes the ability to perform surgical planning at any time or place on a compatible standalone laptop, in addition to on the VUZE System itself.

“Our second generation significantly extends the applicability of the VUZE System across desired surgical workflows and operating room setups,” said David Tolkowsky, founder and CEO of VUZE Medical. “In each of those situations, our aim is to preserve the advantages of common X-ray guidance while addressing its shortcomings.”

Over three million1 surgeries for correcting spinal instability and/or deformation, collectively known as spinal stabilizations, are performed annually worldwide, with as many as a third of those1 in the U.S. These procedures include vertebral fixation with pedicle screws, vertebral fixation coupled with fusion, and vertebral augmentation with synthetic or biological cement. The vast majority of stabilizations treat short spinal segments1. Short-segment surgeries are most often assisted only by standard 2D X-ray. The risk of pedicle screw misplacement has been shown to be greater under X-ray guidance than in navigated surgery 2,3.

Stryker Reports: 1st European Surgeries Completed Using Stryker’s Gamma4 Hip Fracture Nailing System

Stryker
Stryker's Gamma4 Hip Fracture Nailing System is designed to treat hip and femur fractures. Its nail design is informed by Stryker's SOMA database, which includes over 37,000 3D bone models generated from CT scans.

Stryker (NYSE:SYK), a global leader in medical technologies, announced that the first surgeries using the Gamma4 Hip Fracture Nailing System in Europe were completed at the Luzerner Kantonsspital LUKS, at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, and at Les Hôpitaux Universitaires de Strasbourg in France. Stryker will debut the system during a live broadcast event in Germany, on June 4, 2024, highlighting key insights and case discussions.

The Gamma4 Hip Fracture Nailing System is designed to treat hip and femur fractures. Its nail design is informed by Stryker’s SOMA database, which includes over 37,000 3D bone models generated from CT scans. The system received CE certification in November 2023 and has been utilized in over 25,000 cases in North America and Japan.

“This moment marks a significant milestone, as the Gamma4 Hip Fracture Nailing System enters the European market, following the successful launch in the United States,” said Markus Ochs, vice president and general manager of Stryker’s European Trauma & Extremities business. “This system represents Stryker’s unwavering commitment to innovation and excellence in providing advanced medical solutions, empowering surgeons worldwide with options designed to streamline operative flow and improve procedural efficiency.”

The first surgeries in Europe were completed by:

  • Professor Frank Beeres, Chefarzt, PD Dr. med. Björn-Christian Link, Chefarzt und Klinikleiter, Dr. med. Marcel Köppel and Dr. med. Ralf Baumgärtner from the Luzerner Kantonsspital LUKS, Switzerland
  • Professeur Daniel Wagner, Médecin chef de l’unité de Traumatologie and Docteur Kevin Moerenhout from Médecin Associé from CHUV (Centre Hospitalier Universitaire Vaudois) Lausanne, Switzerland
  • Professeur Philippe Adam’s department at the Les Hôpitaux Universitaires de Strasbourg, France

When asked about their experience, the Swiss surgeons agreed that Gamma4 allows for a tailored approach to each patient’s unique anatomy and offers several key features to enhance surgical outcomes. The system’s intuitive instrumentation streamlines procedures and reduces the number of surgical steps required. The surgeons noted the accuracy of the implant fit and the overall quality of the instruments.

Since these initial use cases, more than 35 additional surgeries utilizing the Gamma4 system have been completed in France, Italy, the UK, and Switzerland.

During the live broadcast event scheduled for June 4, 2024, 17:30 CET, Stryker will share key insights and a deep dive into the Gamma4 engineering philosophy. Esteemed faculty, including Professor Dr. Gerhard Schmidmaier from University Hospital Heidelberg, PD Dr. Arvind G. Von Keudell from University Hospital Copenhagen, and Professor Dr. Julio de Caso Rodríguez from Hospital de la Santa Creu i Sant Pau in Barcelona, will lead in-depth case discussions on trauma surgery. Interested healthcare professionals can register for the free event at worldsurgerytour.tv/programs/gamma4-european-premiere-broadcast.

Northwell Cardiothoracic Programs Have Nation’s Highest Success Rates

Northwell Cardiothoracic Programs

Five Northwell Health hospitals received top scores in cardio-thoracic surgery specialties, including certain lung procedures and open-heart surgeries, in the latest ratings from the Society of Thoracic Surgeons (STS).

Five Northwell hospitals – Long Island Jewish Hospital, Lenox Hill Hospital, South Shore University Hospital, Staten Island University Hospital and the Sandra Atlas Bass Heart Hospital at North Shore University Hospital – received three-star ratings in their respective fields – the highest quality rating possible.

LIJ, Lenox Hill, South Shore and Staten Island hospitals received three stars for pulmonary resection for lung cancer, placing them in the top 15 percent nationwide for the procedure – and marking the first time all Northwell facilities received the top rating. LIJ and Lenox Hill also received three-star ratings for lobectomies, placing them in the top 10 percent for that procedure.

A lobectomy is a procedure where an entire lobe of the lung is removed and is commonly used to treat lung cancer. Pulmonary resection is a similar procedure that involves removing part of, or the entirety of, a lung. Northwell performs more than 3,400 lung procedures annually across the health system, many of which are minimally invasive and robotic assisted.

“Northwell hospitals consistently place among the best in the nation in the Society of Thoracic Surgeons’ ratings,” said Alan Hartman, MD, senior vice president and executive director of cardiovascular and thoracic surgery for Northwell. He is also co-director of the Northwell Health Cardiovascular Institute.

“These exceptional ratings from STS are a testament to the collaborative efforts of multiple talented and dedicated individuals and teams across the Northwell Health system,” said Paul C. Lee, MD MPH, system director of thoracic surgery at Northwell Health. “Surgeons, nurses, intensivists, physician assistants, anesthesiologists, pulmonologists and many other healthcare professionals work tirelessly, striving to deliver top-quality care and outcomes for our patients. These ratings just prove the quality of our care and demonstrate the power of teamwork.”

STS also evaluated hospitals for cardiac procedures. Sandra Atlas Bass, South Shore, Staten Island and Lenox Hill hospitals all had the nation’s highest success rates. All four hospitals received three-star quality ratings for isolated coronated artery bypass graft (CABG) surgery, placing them in the top 23 percent nationwide.

Sandra Atlas Bass also received three-stars for isolated aortic valve replacement (AVR), isolated mitral valve (MV) replacement/repair, and CABG+AVR surgery. South Shore was also awarded three stars for CABG+AVR surgery, and Lenox Hill was awarded three stars for isolated MV replacement/repair.

“The facilities that make up Northwell’s Cardiovascular Institute all account for multiple three-star ratings from STS across several programs in the health system,” Dr. Hartman said. “Patients should feel safe knowing they can get high-quality care from world-class physicians at any of our facilities.”

The cardiac report from STS includes data from 964 participants, while the thoracic surgery ratings included data from 293 participants. Both data sets cover the period of January 2021 to December 2023.

Heart disease is the leading killer of Americans. It claims nearly 1 million lives annually, and nearly half of US adults have some form of cardiovascular disease.

Nearly 237,000 people will be diagnosed with lung cancer this year, and more than 127,000 will die from the disease. Lung cancer is the leading cause of cancer death in the United States, and accounts for 20 percent of cancer deaths in the country.

Nearly all the lobectomies performed at LIJ and Lennox Hill are minimally invasive, which leads to faster patient recoveries and less pain. It also allows older patients or those with complex issues to undergo surgery more successfully. Many of the surgeries are also done robotically, more than any other health system in the area.

The rating system from STS measures the overall quality of care and outcomes of thoracic surgery programs across the country. The ratings are calculated by testing whether the hospital’s score is significantly different from the overall STS average for lobectomy and pulmonary resection.

Participation in the STS general thoracic and adult cardiac surgery databases is voluntary, highlighting Northwell’s commitment to quality improvement and transparency of patient outcomes.

Tumor Ablation Market Worth $1.4 Billion

Tumor Ablation Market Report by MarketandMarkets

Technological advancement, new product developments in cryoablation, and the rising incidence of cancer are the major indicators contributing to the growth of the market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142550258

Browse in-depth TOC on “Tumor Ablation Market”

146 – Tables
56 – Figures
192 – Pages

Tumor Ablation Market Scope:

Report Coverage

Details

Market Revenue in 2024

$0.8 billion

Estimated Value by 2029

$1.4 billion

Growth Rate

Poised to grow at a CAGR of 10.0%

Market Size Available for

2022–2029

Forecast Period

2024–2029

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Technology, Product type, mode of treatment, application, end user, and region

Geographies Covered

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Rising healthcare expenditure across emerging economies

Key Market Drivers

Increasing cancer incidence and rising geriatric population

Microwave ablation segment to register significant growth rate over the forecast period of 2024-2029.

Based on the technology, the global market is further segmented into microwave, radiofrequency, high-intensity focused ultrasound, cryoablation, and other technologies. The microwave ablation segment is anticipated to register the highest growth rate over in the near future owing to the promising results of the treatment. This is attributed to the increasing focus on microwave ablation due to its notable benefits such as speed, improved success rate and precise ablation. High efficiency rate of microwave ablation for various cancers is expected to increase its utilization in the end user facilities in coming years.

The generators segment will register a significant growth rate over the forecast period of 2024-2029.

The global tumor ablation market is segmented by product type into generators and probes/electrodes. Major shares of the segment are attributed to the rising patient population and rising adoption of ablation treatment globally. Increasing cancer population due to change in lifestyle, rising obesity, and increasing alcohol consumption contributes to the rise in the number of ablation procedures at hospitals and clinics. The rise in the number of procedures performed will ultimately support the growth of generators segment and is expected to register the significant growth during the forecast period.

Percutaneous ablation segment to register a significant growth rate over the forecast period of 2024-2029.

In terms of mode, global tumor ablation market is divided by mode of treatment into surgical, percutaneous, and laparoscopic ablation. In 2023, the surgical ablation segment held the major share of the market.  Increasing healthcare expenditure and cancer awareness campaigns support the growth of this segment. Educating people through various campaigns for the importance of early detection has been responsible for rise in the number of cancer screening in end user facilities. This ultimately supports the increasing number of ablation procedures and contributes to the exponential growth of the segment.

Liver cancer segment is in application to register a significant growth over the forecast period of 2024-2029.

By application, the global tumor ablation market is segmented by application into liver cancer, lung cancer, kidney cancer, bone cancer, and other applications. The growing trend towards ablation technology over traditional treatments and rising public awareness drive this segment’s growth. Consistent rise in the global cases of hepatocellular carcinoma, clinical studies showing improved success rate, and rising proportion of older age population have supported the growth of liver cancer segment in tumor ablation market.

The hospitals and clinics accounted for the major share of tumor ablation market by end user in 2023.

Based on end users, the tumor ablation market is segmented into hospitals & clinics, cancer care centers, and other end users. The major share of the end-user segment was held by hospitals and clinics in 2023. The increasing prevalence of liver cancer, advancements in tumor ablation technology, and a growing emphasis on non-invasive treatment options contribute to the expanding utilization of ablation treatment within healthcare settings for comprehensive patient care.

The Asia Pacific market will register significant growth in the market during the forecast period.

The Asia Pacific tumor ablation market is estimated to register significant growth from 2024 to 2029. The increasing target patient population, favorable reimbursement scenario, and growing disposable income fuel the APAC region’s market growth. Moreover, the APAC region has experienced a rise in investments by governments and major players, offering significant growth opportunities for the key players.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=142550258

Tumor Ablation Market Dynamics:

Drivers:

  1. Increasing cancer incidence and rising geriatric population

Restraints:

  1. Increasing cancer incidence and rising geriatric population

Opportunities:

  1. Rising healthcare expenditure across emerging economies

Challenge:

  1. Rising adoption of refurbished tumor ablation systems

Key Market Players of Tumor Ablation Industry:

As of 2023, prominent players in the tumor ablation market are Medtronic Plc (Ireland), Johnson & Johnson MedTech (US), and Stryker Corporation (US).

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
  • By Designation: Director-level–10%, C-level–14%, and Others–76%
  • By Region: North America–40%, Europe–30%, Asia Pacific–22%, Latin America–6%, and the Middle East & Africa–2%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=142550258

Tumor Ablation Market – Key Benefits of Buying the Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall tumor ablation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

  • Analysis of key drivers (increasing cancer incidence and rising geriatric population, rising focus on minimally invasive procedures, technological advancements in the field of tumor ablation, rising number of awareness campaigns and early detection), restraints (high cost of tumor ablation systems, unfavorable reimbursement scenario), opportunities (rising healthcare expenditure across emerging countries, increasing number of hospitals), and challenges (rising adoption of refurbished tumor ablation systems, hospital budget cuts) influencing the growth of the tumor ablation market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the tumor ablation market
  • Market Development: Comprehensive information about lucrative markets–the report analyses the tumor ablation market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tumor ablation market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players – such as Johnson & Johnson (US), Medtronic Plc (Ireland), Stryker Corporation (US), Varian Medical Systems, Inc. (US), Olympus (Japan), AngioDynamics, Inc. (US), Boston Scientific Corporation (US) among others.
1...434445...923Page 44 of 923

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330